trending Market Intelligence /marketintelligence/en/news-insights/trending/gbi4M7gvP6JRgYbcSGfgHg2 content esgSubNav
In This List

Johnson & Johnson ends deals talks with Actelion

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Johnson & Johnson ends deals talks with Actelion

Johnson & Johnson ended discussions with Actelion Pharmaceuticals Ltd. regarding a potential transaction as it was not able to reach an agreement that would create adequate value for its shareholders.

Bloomberg News previously reported that Actelion rejected Johnson & Johnson's initial offer, which was priced at CHF246 per share, valuing Actelion at $26 billion.